

S2 Table. Chemotherapy regimens

Regimen	RAD (n=137)	PAD (n=142)
Cisplatin-based chemotherapy		
Etoposide/cisplatin	16 (11.7)	16 (11.3)
Gemcitabine/cisplatin	17 (12.4)	14 (9.9)
Navelbine/cisplatin	16 (11.7)	13 (9.2)
Pemetrexed/cisplatin	12 (8.8)	16 (11.3)
Paclitaxel/ciplatin +/- Avastin	5 (3.6)	6 (4.2)
5-fluorouracil/cisplatin +/- Erbitux	7 (5.1)	9 (6.4)
Docetaxel/5-fluorouracil/cisplatin	5 (3.7)	9 (6.4)
Docetaxel/cisplatin	5 (3.7)	8 (5.7)
TS-1/cisplatin	1 (0.8)	4 (2.9)
Capecitabine/cisplatin +/- Herceptin	6 (4.4)	0
Cyclophosphamide/adriamycin/cisplatin	1 (0.8)	1 (0.8)
Rituximab-FP	1 (0.8)	0
Etoposide/ifosfamide/cisplatin	1 (0.8)	0
Non-cisplatin-based chemotherapy		
Adriamycin/cyclophosphamide	33 (24.1)	31 (21.9)
Adriamycin/cisplatin/vincristine/cyclophosphamide	0	1 (0.8)
Cyclophosphamide/adriamycin/vincristine/cyclophosphamide +/- rituximab	7 (5.2)	11 (7.7)
Etoposide/prednisone/vincristine/cyclophosphamide/adriamycin	0	2 (1.5)
Dacarbazine	1 (0.8)	1 (0.8)
Mesna/doxorubicin/ifosfamide/dacarbazine	1 (0.8)	0
Methotrexate/vinblastine/adriamycin/cisplatin	1 (0.8)	0
Vincristine/dactinomycin/cyclophosphamide	1 (0.8)	0

Values are presented as number (%). RAD, ramosetron, aprepitant, and dexamethasone; PAD, palonosetron, aprepitant, and dexamethasone.